Skip to content

Author

M. MacKinnon

2 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Oct 2026

Simplifying Adult Pneumococcal Vaccination in India: A Cost-Effectiveness Analysis of the 20-Valent Conjugate Vaccine.

INTRODUCTION In India, adult pneumococcal disease prevention relies on the 23‑valent pneumococcal polysaccharide vaccine (PPSV23) and the 13‑ and 20‑valent pneumococcal conjugate vaccines (PCV13, PCV20). Before PCV20 introduction, adults at older age or high risk typically received PCV13 followed by PPSV23, although no...

S. Taur, N. Kulkarni, Sachin Choudhari et al. · 0 citations
Open access Jul 2026

Cost-effectiveness of RSVpreF for the prevention of respiratory syncytial virus illness among high-risk adults in Germany.

Expanding the recommendation to include IC or CMC+/IC adults aged 18-59 years could substantially reduce the clinical burden of RSV-LRTI in Germany; including IC 18-59-year-olds would also be cost-saving.

Erin Quinn, M. MacKinnon, Severin Freisberg et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.